Anti‐CD47 immunotherapy in combination with BCL‐2 inhibitor to enhance anti‐tumor activity in B‐cell lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "Hematological Oncology"
DOI: 10.1002/hon.3009
Abstract: CD47 expressed on cancer cells enables macrophage immune evasion. Blocking CD47 using anti‐CD47 monoclonal antibodies (mAbs) is a promising strategy. The anti‐CD47 mAb TJC4 has anti‐tumor activity but lacks hematological toxicity. Venetoclax, a B‐cell lymphoma… read more here.
Keywords: cell; cell lymphoma; combination; anti cd47 ... See more keywords